Aberrant expression of RAD52, its prognostic impact in rectal cancer and association with poor survival of patients

Vincent Ho; Liping Chung; Amandeep Singh; Vivienne Lea; Askar Abubakar; Stephanie H. Lim; Wei Chua; Weng Ng; Mark Lee; Tara L. Roberts; Paul de Souza; Cheok Soon Lee

doi:10.3390/ijms21051768

Aberrant expression of RAD52, its prognostic impact in rectal cancer and association with poor survival of patients

Vincent Ho, Liping Chung, Amandeep Singh, Vivienne Lea, Askar Abubakar, Stephanie H. Lim, Wei Chua, Weng Ng, Mark Lee, Tara L. Roberts, Paul de Souza, Cheok Soon Lee

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

The DNA damage response enables cells to survive and maintain genome integrity. RAD52 is a DNA-binding protein involved in the homologous recombination in DNA repair, and is important for the maintenance of tumour genome integrity. We investigated possible correlations between RAD52 expression and cancer survival and response to preoperative radiotherapy. RAD52 expression was examined in tumour samples from 179 patients who underwent surgery for rectal cancer, including a sub-cohort of 40 patients who were treated with neoadjuvant therapy. A high score for RAD52 expression in the tumour centre was significantly associated with worse disease-free survival (DFS; p = 0.045). In contrast, reduced RAD52 expression in tumour centre samples from patients treated with neoadjuvant therapy (n = 40) significantly correlated with poor DFS (p = 0.025) and overall survival (OS; p = 0.048). Our results suggested that RAD52 may have clinical value as a prognostic marker of tumour response to neoadjuvant radiation and both disease-free status and overall survival in patients with rectal cancer.

Original language	English
Article number	1768
Number of pages	16
Journal	International Journal of Molecular Sciences
Volume	21
Issue number	5
DOIs	https://doi.org/10.3390/ijms21051768
Publication status	Published - 2020

Open Access - Access Right Statement

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Keywords

DNA damage
biochemical markers
cancer
prognosis
rectum

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms21051768

Cite this

@article{5ffcef27c7d9461f95fd4362eb56ee0a,

title = "Aberrant expression of RAD52, its prognostic impact in rectal cancer and association with poor survival of patients",

abstract = "The DNA damage response enables cells to survive and maintain genome integrity. RAD52 is a DNA-binding protein involved in the homologous recombination in DNA repair, and is important for the maintenance of tumour genome integrity. We investigated possible correlations between RAD52 expression and cancer survival and response to preoperative radiotherapy. RAD52 expression was examined in tumour samples from 179 patients who underwent surgery for rectal cancer, including a sub-cohort of 40 patients who were treated with neoadjuvant therapy. A high score for RAD52 expression in the tumour centre was significantly associated with worse disease-free survival (DFS; p = 0.045). In contrast, reduced RAD52 expression in tumour centre samples from patients treated with neoadjuvant therapy (n = 40) significantly correlated with poor DFS (p = 0.025) and overall survival (OS; p = 0.048). Our results suggested that RAD52 may have clinical value as a prognostic marker of tumour response to neoadjuvant radiation and both disease-free status and overall survival in patients with rectal cancer.",

keywords = "DNA damage, biochemical markers, cancer, prognosis, rectum",

author = "Vincent Ho and Liping Chung and Amandeep Singh and Vivienne Lea and Askar Abubakar and Lim, {Stephanie H.} and Wei Chua and Weng Ng and Mark Lee and Roberts, {Tara L.} and {de Souza}, Paul and Lee, {Cheok Soon}",

year = "2020",

doi = "10.3390/ijms21051768",

language = "English",

volume = "21",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI AG",

number = "5",

}

TY - JOUR

T1 - Aberrant expression of RAD52, its prognostic impact in rectal cancer and association with poor survival of patients

AU - Ho, Vincent

AU - Chung, Liping

AU - Singh, Amandeep

AU - Lea, Vivienne

AU - Abubakar, Askar

AU - Lim, Stephanie H.

AU - Chua, Wei

AU - Ng, Weng

AU - Lee, Mark

AU - Roberts, Tara L.

AU - de Souza, Paul

AU - Lee, Cheok Soon

PY - 2020

Y1 - 2020

N2 - The DNA damage response enables cells to survive and maintain genome integrity. RAD52 is a DNA-binding protein involved in the homologous recombination in DNA repair, and is important for the maintenance of tumour genome integrity. We investigated possible correlations between RAD52 expression and cancer survival and response to preoperative radiotherapy. RAD52 expression was examined in tumour samples from 179 patients who underwent surgery for rectal cancer, including a sub-cohort of 40 patients who were treated with neoadjuvant therapy. A high score for RAD52 expression in the tumour centre was significantly associated with worse disease-free survival (DFS; p = 0.045). In contrast, reduced RAD52 expression in tumour centre samples from patients treated with neoadjuvant therapy (n = 40) significantly correlated with poor DFS (p = 0.025) and overall survival (OS; p = 0.048). Our results suggested that RAD52 may have clinical value as a prognostic marker of tumour response to neoadjuvant radiation and both disease-free status and overall survival in patients with rectal cancer.

AB - The DNA damage response enables cells to survive and maintain genome integrity. RAD52 is a DNA-binding protein involved in the homologous recombination in DNA repair, and is important for the maintenance of tumour genome integrity. We investigated possible correlations between RAD52 expression and cancer survival and response to preoperative radiotherapy. RAD52 expression was examined in tumour samples from 179 patients who underwent surgery for rectal cancer, including a sub-cohort of 40 patients who were treated with neoadjuvant therapy. A high score for RAD52 expression in the tumour centre was significantly associated with worse disease-free survival (DFS; p = 0.045). In contrast, reduced RAD52 expression in tumour centre samples from patients treated with neoadjuvant therapy (n = 40) significantly correlated with poor DFS (p = 0.025) and overall survival (OS; p = 0.048). Our results suggested that RAD52 may have clinical value as a prognostic marker of tumour response to neoadjuvant radiation and both disease-free status and overall survival in patients with rectal cancer.

KW - DNA damage

KW - biochemical markers

KW - cancer

KW - prognosis

KW - rectum

UR - http://hdl.handle.net/1959.7/uws:54857

U2 - 10.3390/ijms21051768

DO - 10.3390/ijms21051768

M3 - Article

SN - 1661-6596

VL - 21

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 5

M1 - 1768

ER -

Aberrant expression of RAD52, its prognostic impact in rectal cancer and association with poor survival of patients

Abstract

Open Access - Access Right Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this